These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Selective inhibition of replication of the AIDS-associated virus HTLV-III/LAV by synthetic D-penicillamine. Chandra P; Sarin PS Arzneimittelforschung; 1986 Feb; 36(2):184-6. PubMed ID: 3008768 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of HTLV-III/LAV replication by foscarnet. Sarin PS; Taguchi Y; Sun D; Thornton A; Gallo RC; Oberg B Biochem Pharmacol; 1985 Nov; 34(22):4075-9. PubMed ID: 2415134 [No Abstract] [Full Text] [Related]
5. Effects of a novel compound (AL 721) on HTLV-III infectivity in vitro. Sarin PS; Gallo RC; Scheer DI; Crews F; Lippa AS N Engl J Med; 1985 Nov; 313(20):1289-90. PubMed ID: 2414659 [No Abstract] [Full Text] [Related]
6. Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1. Sarin PS; Sun DK; Thornton AH; Naylor PH; Goldstein AL Science; 1986 May; 232(4754):1135-7. PubMed ID: 3010464 [TBL] [Abstract][Full Text] [Related]
7. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). Balzarini J; Mitsuya H; De Clercq E; Broder S Int J Cancer; 1986 Mar; 37(3):451-7. PubMed ID: 2419266 [TBL] [Abstract][Full Text] [Related]
8. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. Yamamoto JK; Barré-Sinoussi F; Bolton V; Pedersen NC; Gardner MB J Interferon Res; 1986 Apr; 6(2):143-52. PubMed ID: 2425014 [TBL] [Abstract][Full Text] [Related]
9. AIDS update: HTLV-III/LAV infection. Cassens BJ Pa Med; 1986 Jan; 89(1):24-6. PubMed ID: 3005945 [No Abstract] [Full Text] [Related]
10. AIDS drug shows promise in preliminary clinical trial. Marx JL Science; 1986 Mar; 231(4745):1504-5. PubMed ID: 3006242 [No Abstract] [Full Text] [Related]
11. Approaches to AIDS therapy. Klatzmann D; Montagnier L Nature; 1986 Jan 2-8; 319(6048):10-11. PubMed ID: 3001533 [No Abstract] [Full Text] [Related]
12. Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro. Mitsuya H; Matsushita S; Yarchoan R; Broder S Princess Takamatsu Symp; 1984; 15():277-88. PubMed ID: 6085846 [TBL] [Abstract][Full Text] [Related]
13. Antiviral strategies and vaccines against HTLV III/LAV. Dalgleish AG J R Coll Physicians Lond; 1986 Oct; 20(4):258-67. PubMed ID: 2430099 [No Abstract] [Full Text] [Related]
14. In search of specific inhibitors of retrovirus replication. De Clercq E; Balzarini J Antiviral Res; 1985; Suppl 1():89-94. PubMed ID: 2417552 [No Abstract] [Full Text] [Related]
15. [LAV/HTLV-III--new discoveries on its properties, isolation, vaccination and therapy]. Asjö B; Morfeldt-Månson L; Fenyö EM; Böttiger B; Biberfeld G; Espmark A Lakartidningen; 1985 May; 82(20):1870-5. PubMed ID: 2987633 [No Abstract] [Full Text] [Related]
16. [Breakthrough in AIDS research--new group of more potent and more selective anti-AIDS compounds]. Schweiz Rundsch Med Prax; 1990 Apr; 79(15):476-7. PubMed ID: 2336503 [No Abstract] [Full Text] [Related]
17. Prospects of therapy for infections with human T-lymphotropic virus type III. Hirsch MS; Kaplan JC Ann Intern Med; 1985 Nov; 103(5):750-5. PubMed ID: 2413793 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapeutic approaches for the treatment of AIDS. Oberg B Arzneimittelforschung; 1988 Feb; 38(2):325-6. PubMed ID: 3370082 [No Abstract] [Full Text] [Related]